Characterisation of CD8+T cell responses induced by therapeutic vaccination with HIV-1 clade A gag DNA- and recombinant modified vaccinia virus Ankara (MVA)-vectored vaccines in HIV-1 infected individuals recieving highly active antiretroviaral therapy

Characterisation of CD8+T cell responses induced by therapeutic vaccination with HIV-1 clade A gag DNA- and recombinant modified vaccinia virus Ankara (MVA)-vectored vaccines in HIV-1 infected individuals recieving highly active antiretroviaral therapy

Bibliographic Details
Main Author:	Yang, Hongbing
Published:	University of Oxford 2007
Subjects:	616.9792079
Online Access:	http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.442987

Similar Items

Ribozymes against the chemokine receptors CCR5 and CXCR4 for inhibiting HIV-1
by: Qureishi, Amer Naveed
Published: (2003)

A study of the humoral immune system in human immunodeficiency virus disease
by: Davies, Edward Thomas
Published: (2000)

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
by: Jeffrey R Currier, et al.
Published: (2010-11-01)

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
by: Bauer A, et al.
Published: (2012-09-01)

Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).
by: Rachael Chiam, et al.
Published: (2009-06-01)

Clinical evaluation of a candidate HIV-1 Clade A DNA/MVA vaccine designed for Kenya
by: Mwau, Matilu
Published: (2004)

Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.
by: Maria L Knudsen, et al.
Published: (2015-01-01)

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
by: Arwen F. Altenburg, et al.
Published: (2014-07-01)

Induction of HIV-1 Gag-specific memory T cells in Chacma baboons by MVA prime and VLP boost vaccine regimen
by: Singh V, et al.
Published: (2012-09-01)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
by: Patricia Pérez, et al.
Published: (2020-02-01)

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.
by: Susan P Buchbinder, et al.
Published: (2017-01-01)

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.
by: Richard Stebbings, et al.
Published: (2012-01-01)

Genome Sequencing of a Camelpox Vaccine Reveals Close Similarity to Modified <i>Vaccinia virus</i> Ankara (MVA)
by: Maurilia Marcacci, et al.
Published: (2020-07-01)

DNA/MVA Vaccines for HIV/AIDS
by: Smita S. Iyer, et al.
Published: (2014-02-01)

Recombinant Salmonella enterica Serovar Typhimurium as a Vaccine Vector for HIV-1 Gag
by: Nyasha Chin'ombe
Published: (2013-08-01)

SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells.
by: Ruikang Liu, et al.
Published: (2019-05-01)

Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice.
by: Ros Chapman, et al.
Published: (2017-01-01)

Immunomonitoring technologies for the evaluation of Modified Vaccinia Virus Ankara expressing HIV-1 nef as a vaccine against AIDS
by: Kutscher, Sarah
Published: (2010)

The recognition of HIV-1 consensus group M Gag and Nef peptide reagents in mono- and multi-clade epidemics: implications for HIV vaccine design
by: Zembe L, et al.
Published: (2012-09-01)

Recombinant BCG expressing HIV-1 C GAG : selection of the vaccine gene and construction and evaluation as a vaccine candidate
by: Thomas, Robin
Published: (2014)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
by: Matthew G Cottingham, et al.
Published: (2008-02-01)

Diseño y construcción de vectores de transferencia para la obtención de virus vaccinia Ankara modificado (MVA) recombinantes Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)
by: M. F. Ferrer, et al.
Published: (2007-09-01)

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.
by: Sandhya Vasan, et al.
Published: (2010-01-01)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
by: Podola L, et al.
Published: (2012-09-01)

A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses
by: Beatriz Perdiguero, et al.
Published: (2019-02-01)

A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.
by: Juan García-Arriaza, et al.
Published: (2011-01-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
by: Matthew G. Cottingham, et al.
Published: (2011-01-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA).
by: Matthew G. Cottingham, et al.
Published: (2011-01-01)

Detection of broad functional gag-specific CD4+ T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen
by: Rowland-Jones Sarah L, et al.
Published: (2006-12-01)

Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary?
by: Zirkel Amy, et al.
Published: (2005-04-01)

Construction and assessment of HIV-1 clade A vaccine candidates
by: Nkolola, Joseph P.
Published: (2004)

Progress toward a universal H5N1 vaccine: a recombinant modified vaccinia virus Ankara-expressing trivalent hemagglutinin vaccine.
by: Mookkan Prabakaran, et al.
Published: (2014-01-01)

Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.
by: Patricia J Munseri, et al.
Published: (2015-01-01)

OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees
by: Biberfeld G, et al.
Published: (2009-10-01)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
by: Munseri P, et al.
Published: (2012-09-01)

Studies of heterologous regimens for HIV-1 vaccines by rBCG and rMVA vectors
by: Hopkins, Richard
Published: (2010)

P19-53 LB. Priming with recombinant BCG expressing HIV-1 Gag or RT and boosting with recombinant MVA induces an effective immune response in mice
by: Williamson A, et al.
Published: (2009-10-01)

Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice.
by: Rosamund Chapman, et al.
Published: (2013-01-01)

HIV-Neutralising response to recombinant, cross-clade, adjuvanted, VLP-forming vaccine candidates
by: Bridge, Simon Harwood
Published: (2007)

Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.
by: Rosamund Chapman, et al.
Published: (2012-01-01)